BridgeBio Pharma, Inc. — Director's Dealing 2023

Jun 23, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-06-21

Reporting Person: DANIELS RONALD J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-21	Stock Option (right to buy)	$16.75	A	51501	Acquired	2033-06-21	Common Stock (51501)	Direct

Footnotes

F1: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.